MV140黏膜细菌疫苗可改善尿路感染实验模型中尿路致病性细菌的清除情况。
MV140 mucosal bacterial vaccine improves uropathogenic clearance in an experimental model of urinary tract infection.
作者信息
Saz-Leal Paula, Ligon Marianne M, Diez-Rivero Carmen M, García-Ayuso Diego, Mohanty Soumitra, Conejero Laura, Brauner Annelie, Subiza José L, Mysorekar Indira U
机构信息
Inmunotek, S.L. Alcalá de Henares, Madrid, Spain.
Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO, USA.
出版信息
Res Sq. 2023 Jun 7:rs.3.rs-2992611. doi: 10.21203/rs.3.rs-2992611/v1.
MV140 is a mucosal vaccine of inactivated whole bacteria () with clinical efficacy against recurrent urinary tract infections (UTIs). Here, MV140 was evaluated in a murine model of acute uropathogenic (UPEC)-induced UTI using the UTI89 strain. MV140 vaccination resulted in UPEC clearance, concomitant with increased influx of myeloid cells in urine, CD4+ T cells in the bladder, and a systemic adaptive immune response to both MV140-containing and UTI89.
MV140是一种灭活全菌粘膜疫苗，对复发性尿路感染（UTI）具有临床疗效。在此，使用UTI89菌株在急性尿路致病性大肠杆菌（UPEC）诱导的UTI小鼠模型中对MV140进行了评估。MV140疫苗接种导致UPEC清除，同时尿液中髓样细胞、膀胱中CD4 + T细胞的流入增加，以及对含MV140制剂和UTI89的全身适应性免疫反应。
Zotero 插件